Dr. Michael Vogelbaum, MD

• Neurosurgery

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Barnes Hospital

  Internship Hospital, 1993

• University Va

  Medical School, 1992

• Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations, 2021-03-19

• The MIF promoter SNP rs755622 is associated with immune activation in glioblastoma, 2023-07-10

• Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial, 2023-05-15

• Deep neural network to locate and segment brain tumors outperformed the expert technicians who created the training data, 2020-10-16

• Convection-enhanced drug delivery for glioblastoma: a review, 2021-02-21

• Myeloid-derived suppressor cell subsets drive glioblastoma growth in a sex-specific manner, 2020-04-16

• Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases, 2021-03-04

• Replicative Instability Drives Cancer Progression, 2022-10-26

• Modified RANO (mRANO), iRANO, and standard RANO response to convection-enhanced delivery of IL4R-targeted immunotoxin MDNA55 in recurrent glioblastoma, 2021-04-16

• Molecular determinants of outcomes in meningiomas, 2022-08-12

• Preclinical modeling of surgery and steroid therapy for glioblastoma reveals changes in immunophenotype that are associated with tumor growth and outcome, 2021-02-04

• Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression, 2020-06-18

• Author Correction: Federated learning enables big data for rare cancer boundary detection, 2023-01-26

• Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study, 2021-05-14

• High-risk Meningioma: Initial Outcomes From NRG Oncology/RTOG 0539, 2019-11-29

• Federated learning enables big data for rare cancer boundary detection, 2022-12-05

• The Meningioma Enhancer Landscape Delineates Novel Subgroups and Drives Druggable Dependencies, 2020-07-23

• Improving Brain Metastases Outcomes Through Therapeutic Synergy Between Stereotactic Radiosurgery and Targeted Cancer Therapies, 2022-03-02

• Convection-Enhanced Delivery of a First-in-Class Anti-ß1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging, 2020-12-30

• Capecitabine and stereotactic radiation in the management of breast cancer brain metastases, 2021-05-15

• Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post-hoc analysis of the EORTC randomized phase 3 CATNON trial, 2022-06-13

• Distinct cell adhesion signature defines glioblastoma myeloid-derived suppressor cell subsets, 2022-11-15

• The NXDC-MEN-301 Study on 5-ALA for Meningiomas Surgery: An Innovative Study Design for the Assessing the Benefit of Intra-Operative Fluorescence Imaging, 2022-08-06